1
|
Singh IR, Mitra S. Interaction of chlorpropamide with serum albumin: Effect on advanced glycated end (AGE) product fluorescence. Spectrochim Acta A Mol Biomol Spectrosc 2019; 206:569-577. [PMID: 30189383 DOI: 10.1016/j.saa.2018.08.055] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/09/2018] [Revised: 08/17/2018] [Accepted: 08/27/2018] [Indexed: 06/08/2023]
Abstract
Carrier proteins like bovine or human serum albumin (BSA and HSA, respectively) are prone to glycation as compared to the other available proteins. In this study, reducing sugars such as l-arabinose (ara), d-(-) galactose (gal) and d-(-) fructose (fru) were used to create model glycated serum albumins and binding ability of these with well-known antidiabetic drug chlorpropamide (CPM) was monitored. Fluorescence quenching experiment revealed that interaction of CPM with native as well as glycated albumins undergoes through a ground state complex formation. CPM binds strongly to glycated HSA with arabinose (gHSAara) as compared to other glycated systems and to the native proteins. CPM interacts through Van der Waals and hydrogen bonding interaction to glycated BSA by d-(-) fructose (gBSAfru) and also with native HSA; whereas, it's interaction with BSA and others glycated systems like gBSAara, gBSAgal and gHSAara occurs primarily through hydrophobic interaction. CPM showed an enhancement in the production of the advanced glycated end products (AGE) in all the glycated proteins. The difference in the binding capability of CPM to differently glycated albumins could be a major model to understand the drug carrying capacity of the glycated serum albumins.
Collapse
Affiliation(s)
- Imocha Rajkumar Singh
- Centre for Advanced Studies in Chemistry, North-Eastern Hill University, Shillong 793 022, India
| | - Sivaprasad Mitra
- Centre for Advanced Studies in Chemistry, North-Eastern Hill University, Shillong 793 022, India.
| |
Collapse
|
2
|
Sartor G, Melander A, Scherstén B, Wåhlin-Boll E. Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers. Acta Med Scand 2009; 208:301-7. [PMID: 6778079 DOI: 10.1111/j.0954-6820.1980.tb01199.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The single-dose kinetics and effects of tolbutamide (500 mg), chlorpropamide (250 mg), glibenclamide (5 mg) and glipizide (5 mg) were compared in 7 healthy male volunteers by measurements of serum concentrations of the drugs and of plasma insulin and blood glucose. The drugs were administered both on an empty stomach and together with a standardized breakfast. The concentrations of tolbutamide and chlorpropamide were measured by gas chromatography, those of glipizide with high-pressure liquid chromatography, those of glibenclamide and insulin by radioimmunoassay and those of glucose by the hexokinase method. Glipizide and glibenclamide were more potent inducers of insulin release and blood glucose reduction than tolbutamide and chlorpropamide. As the concentrations of the former two drugs were in the range of nmol/l and those of the latter two in the mumol/l range, the findings support the notion that the intrinsic activity of the two second-generation sulfonylureas is at least 1 000 times greater than that of the two first-generation drugs. Glipizide seemed to be a more potent and more rapid insulin releaser than glibenclamide, but this may be secondary to biopharmaceutic differences between the two preparations. The bioavailability of glipizide was apparently greater than that of glibenclamide. Both glibenclamide (t 1/2 = 1.8 h) and glipizide (t 1/2 = 4.3 h) showed much shorter elimination half-lives than tolbutamide (7 h) and chlorpropamide (34 h). It seems probable, however, that these half-lives are not fully informative as to the duration of action of the drugs.
Collapse
|
3
|
Shon JH, Yoon YR, Kim MJ, Kim KA, Lim YC, Liu KH, Shin DH, Lee CH, Cha IJ, Shin JG. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol 2005; 59:552-63. [PMID: 15842554 PMCID: PMC1884838 DOI: 10.1111/j.1365-2125.2005.02364.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
AIMS We evaluated the involvement of cytochrome P450 (CYP) isoforms 2C9 and 2C19 in chlorpropamide 2-hydroxylation in vitro and in chlorpropamide disposition in vivo. METHODS To identify CYP isoforms(s) that catalyse 2-hydroxylation of chlorpropamide, the incubation studies were conducted using human liver microsomes and recombinant CYP isoforms. To evaluate whether genetic polymorphisms of CYP2C9 and/or CYP2C19 influence the disposition of chlorpropamide, a single oral dose of 250 mg chlorpropamide was administered to 21 healthy subjects pregenotyped for CYP2C9 and CYP2C19. RESULTS In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively. In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein). Formation of 2-OH-chlorpropamide in human liver microsomes was significantly inhibited by sulfaphenazole, but not by S-mephenytoin, ketoconazole, quinidine, or furafylline. In in vivo clinical trials, eight subjects with the CYP2C9*1/*3 genotype exhibited significantly lower nonrenal clearance [*1/*3 vs.*1/*1: 1.8 +/- 0.2 vs. 2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype. In contrast, no differences in chlorpropamide pharmacokinetics were observed for subjects with the CYP2C19 extensive metabolizer vs. poor metabolizer genotypes. CONCLUSIONS These results suggest that chlorpropamide disposition is principally determined by CYP2C9 activity in vivo, although both CYP2C9 and CYP2C19 have a catalysing activity of chlorpropamide 2-hydroxylation pathway.
Collapse
Affiliation(s)
- Ji-Hong Shon
- Department of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine and Clinical Pharmacology Centre, Busan Paik HospitalBusan
| | - Young-Ran Yoon
- Department of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine and Clinical Pharmacology Centre, Busan Paik HospitalBusan
| | - Min-Jung Kim
- Department of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine and Clinical Pharmacology Centre, Busan Paik HospitalBusan
| | - Kyoung-Ah Kim
- Department of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine and Clinical Pharmacology Centre, Busan Paik HospitalBusan
| | - Young-Chae Lim
- Department of Pharmacology, Chonnam National University College of MedicineKwangju
| | - Kwang-Hyeon Liu
- Department of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine and Clinical Pharmacology Centre, Busan Paik HospitalBusan
| | - Dong-Hoon Shin
- Department of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine and Clinical Pharmacology Centre, Busan Paik HospitalBusan
- Department of General Surgery, Kosin University College of MedicineBusan, Korea
| | - Chung Han Lee
- Department of General Surgery, Kosin University College of MedicineBusan, Korea
| | - In-June Cha
- Department of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine and Clinical Pharmacology Centre, Busan Paik HospitalBusan
| | - Jae-Gook Shin
- Department of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine and Clinical Pharmacology Centre, Busan Paik HospitalBusan
| |
Collapse
|
4
|
Choudhury D, Thompson A, Stojanoff V, Langermann S, Pinkner J, Hultgren SJ, Knight SD. X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science 1999; 285:1061-6. [PMID: 10446051 DOI: 10.1126/science.285.5430.1061] [Citation(s) in RCA: 465] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Type 1 pili-adhesive fibers expressed in most members of the Enterobacteriaceae family-mediate binding to mannose receptors on host cells through the FimH adhesin. Pilus biogenesis proceeds by way of the chaperone/usher pathway. The x-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli at 2.5 angstrom resolution reveals the basis for carbohydrate recognition and for pilus assembly. The carboxyl-terminal pilin domain of FimH has an immunoglobulin-like fold, except that the seventh strand is missing, leaving part of the hydrophobic core exposed. A donor strand complementation mechanism in which the chaperone donates a strand to complete the pilin domain explains the basis for both chaperone function and pilus biogenesis.
Collapse
Affiliation(s)
- D Choudhury
- Department of Molecular Biology, Uppsala Biomedical Center, Swedish University of Agricultural Sciences, Box 590, S-753 24 Uppsala, Sweden
| | | | | | | | | | | | | |
Collapse
|
5
|
Affiliation(s)
- J O Miners
- Department of Clinical Pharmacology, Flinders Medical Centre, Bedford Park, South Australia
| | | |
Collapse
|
6
|
Kragh-Hansen U. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. Mol Pharmacol 1988; 34:160-71. [PMID: 3412320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
The relations between the single high affinity binding sites for azapropazone, phenylbutazone, chlorpropamide, sulfathiazole, and iophenoxate and the binding regions of human serum albumin represented by the marker ligands diazepam, phenol red, salicylate, and warfarin were examined by a series of competition experiments. Binding was determined by equilibrium dialysis at pH 7.0. In order to ensure an accurate analysis of the competition experiment, the number of moles of ligand bound per mole of protein was usually 0.4 or less to minimize ligand binding to weaker sites. Furthermore, binding of both ligands was determined in all experiments (except for iophenozate). None of the test ligands competed with diazepam for a common high affinity binding site, but, surprisingly, they were all able to displace two or three of the other marker ligands according to a competitive scheme. These findings show, first, the existence of a particular serum albumin region for high affinity binding of diazepam. Secondly, they imply that it is not necessary to assume the existence of new drug binding regions beyond those existing for phenol red, salicylate, and warfarin. On the contrary, the relatively many examples of competitive binding indicate that the binding regions represented by the last-mentioned three marker ligands are placed quite close to each other in the albumin molecule in a common region, which is suggested to be located at subdomains 1C and 2A-B. The region must be relatively large, because in some cases independent high affinity binding of pairs of ligands is observed. It is probably also rather flexible, inasmuch as no clear relation could be found between the chemical structure of the test ligands and the two or three marker ligands with which they compete. Correlations between primary association constants and partition coefficients for both marker ligands and test ligands, in the unionized forms, between n-hexane or 1-octanol and aqueous media showed that hydrophobic forces are important for the binding processes. However, the data also showed that other attractive forces must be operative as well.
Collapse
Affiliation(s)
- U Kragh-Hansen
- Institute of Medical Biochemistry, University of Aarhus, Denmark
| |
Collapse
|
7
|
Neuvonen PJ, Kärkkäinen S, Lehtovaara R. Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. Eur J Clin Pharmacol 1987; 32:297-301. [PMID: 3595702 DOI: 10.1007/bf00607578] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The effects of liver enzyme induction and of urine pH on the pharmacokinetics of chlorpropamide have been studied. A single oral dose of chlorpropamide 250 mg was administered to 8 patients on antiepileptic drugs (phenytoin, carbamazepine) and to 8 healthy volunteers. The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h). The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1). The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%). Neither the volume of distribution nor the clearance of the free fraction of chlorpropamide differed significantly between the groups. There was a significant correlation between the half-lives of chlorpropamide and antipyrine, and the half-life of chlorpropamide also had at least as good an inverse correlation with the urinary excretion of unchanged chlorpropamide. The renal clearance of chlorpropamide correlated well with urine pH and was almost 100-fold higher at pH 7 than at pH 5. Both the metabolic and renal clearances of chlorpropamide are important in its elimination. At urine pH higher than 6.5-7, the renal clearance of chlorpropamide represents more than half its total clearance regardless the degree of induction of liver enzymes.
Collapse
|
8
|
Abstract
This study compared the pharmacokinetics of chlorpropamide (C) when administered alone, or in combination with sucralfate (S) to evaluate whether a drug-drug interaction exists between these two agents in vivo. A two-way, randomized, cross-over study was performed in 12 healthy male volunteers who received 250 mg C alone or were pretreated with S qid for two days and then received a single 250-mg dose of C with S on day 3 and continued to take sucralfate throughout the day while serial blood samples were drawn. High-performance liquid chromatography determination of plasma concentrations found there to be no statistically significant differences in maximum concentration, time to maximum concentration, elimination rate constant, or area under the concentration-time curve from 0 to 96 hours. However, there was a statistically significant difference in the area under the curve from 0 to infinity data (P less than .05). The authors conclude that there appears to be no drug interaction between sucralfate and chlorpropamide when given concurrently; however, a trend towards less drug availability was seen that may warrant a future multiple-dose study to further evaluate the significance of this finding.
Collapse
|
9
|
Deshpande AV, Agrawal DK. Bioavailability studies of chlorpropamide from its polyvinylpyrrolidone coprecipitate. Pharmazie 1985; 40:496-7. [PMID: 4048258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
10
|
Feldman JM. Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy 1985; 5:43-62. [PMID: 3923453 DOI: 10.1002/j.1875-9114.1985.tb03404.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Glyburide, a second-generation hypoglycemic sulfonylurea, is 200 times as potent as tolbutamide. This increase is due to greater intrinsic hypoglycemic potency of the molecule rather than to a prolonged biologic half-life. Glyburide is inactivated by the liver to 4-trans-hydroxyglyburide and 3-cis-hydroxyglyburide; 50% of these compounds is excreted in the urine and 50% in the bile. Although the serum concentration of glyburide can be measured by radioimmunoassay and high-performance liquid chromatography, the importance of its serum concentration in the reduction of hyperglycemia is not yet established. Glyburide has a therapeutic effectiveness comparable to that of the first-generation sulfonylurea chlorpropamide; however, it has a lower frequency of adverse effects. To date it has a low frequency of clinically significant interactions with other drugs. Glyburide should not be prescribed for patients with liver disease or significant renal disease. Because glyburide is a potent hypoglycemic agent, it should be prescribed in small initial doses, particularly for elderly patients with diabetes. At the present time there is no definite evidence that it modifies the increased risk of cardiovascular disease of diabetic patients. Although glyburide is a potent stimulator of pancreatic insulin secretion after short-term administration, an additional mechanism of action during long-term administration is to decrease the resistance of muscle and liver to the action of insulin. It is a useful medication for patients with type II diabetes whose hyperglycemia is not adequately reduced by dietary management and exercise. It can be used as the initial drug in these patients or as the replacement drug for those with primary or secondary failure during therapy with first-generation sulfonylureas.
Collapse
|
11
|
Abstract
The oral hypoglycemic agents, chlorpropamide (CP) and tolbutamide (TB) are known to elicit a clinical disulfiram-ethanol reaction (DER) when consumed with alcohol. In rats, this DER is manifested in vivo by the elevation of blood acetaldehyde (AcH) levels, a consequence of the inhibition of hepatic aldehyde dehydrogenase (AIDH). Administration of CP or TB to rats (1.0 mmol/kg, IP), followed by ethanol one hour before sacrifice, raised blood AcH levels 12- and 2-times that of control animals, respectively for CP and TB when measured at 3 hours, and 20-fold and 8-fold at 16 hours post drug administration. CP and TB had no effect on AIDH activity when incubated with either intact or osmotically disrupted rat liver mitochondria, indicating that a metabolite of CP or TB is responsible for the inhibition of AIDH in vivo. Hydrolysis products of CP, the 2'-hydroxylated products of CP, tolpropamide and tolethamide, or the 3'-hydroxylated analogs of CP and tolpropamide, were uniformly inactive in elevating ethanol-derived blood AcH. Pretreatment of rats with 3-amino-1,2,4-triazole or SKF-525A had no effect on the elevation of blood AcH mediated by CP or TB, while phenobarbital pretreatment decreased blood AcH by 69%. Although our results clearly indicated that side chain hydroxylation and subsequent oxidation do not play a role in AIDH inhibition by CP or TB, the nature of the side chain attached to the sulfonylurea moiety appears to influence this inhibitory activity in vivo. Thus, the order of activity in the homologous series was, chlorpropamide greater than chlorbutamide greater than chlorethamide much greater than chlormethamide, chlorisopropamide = 0.
Collapse
|
12
|
Hellman B, Sehlin J, Täljedal IB. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets. Acta Endocrinol (Copenh) 1984; 105:385-90. [PMID: 6230850 DOI: 10.1530/acta.0.1050385] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Six hypoglycaemic sulphonylurea compounds were compared with regard to their ability to bind to beta-cell-rich pancreatic islets microdissected from ob/ob-mice. Glibenclamide differed from carbutamide, tolbutamide, chlorpropamide, glibornuride and glipizide in not being rapidly bound to an equilibrium, but accumulating progressively in amounts far exceeding the water space. An inhibitor of the anion channels in the beta-cell membrane, 4-acetamido-4'-isothiocyanate-stilbene-2,2'-disulphonic acid (SITS), suppressed the islet uptake of glibenclamide and to some extent also that of carbutamide and glibornuride. The unusual uptake characteristics of glibenclamide had their counterpart in a retardation of its maximal action in promoting the entry of Ca2+ into the beta-cells.
Collapse
|
13
|
Tsukiai S, Fukuchi H, Yoshida M, Kumagai M, Kitaura T, Arai S, Yata N. [Effect of free fatty acids on renal clearance of chlorpropamide in rabbits]. YAKUGAKU ZASSHI 1983; 103:1313-8. [PMID: 6677719 DOI: 10.1248/yakushi1947.103.12_1313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
14
|
Abstract
The clinical pharmacology of glipizide and other sulfonylureas is briefly reviewed. Reevaluation of the University Group Diabetes Program data suggests that sulfonylureas do not increase cardiovascular mortality. Instead, a long-term study of subjects with impaired glucose tolerance indicates that sulfonylureas reduce the frequency of cardiovascular morbidity and can postpone or even prevent the development of impaired glucose tolerance to manifest diabetes. It is likely that all sulfonylureas have the same principal mechanism(s) of action but that they differ in potency and pharmacokinetics, resulting in considerable clinical differences. Thus, glipizide and glibenclamide (glyburide) are much more potent than tolbutamide and chlorpropamide. Glipizide has the most rapid absorption and onset of action, as well as the shortest half-life and effect-duration; hence the risk of long-lasting hypoglycemia is minute. Glipizide has complete bioavailability, and its blood glucose-lowering effect is improved when it is given before breakfast. Glipizide may be administered once daily without loss of therapeutic efficacy.
Collapse
|
15
|
|
16
|
Abstract
The effects of activated charcoal, sodium bicarbonate, and ammonium chloride by mouth on chlorpropamide kinetics was studied in six healthy subjects. Activated charcoal, 50 gm, given immediately after 250 mg chlorpropamide reduced its absorption by 90%, but when given in repeated doses from 6 hr on (50 gm followed by 12.5 gm at 6-hr intervals) it did not shorten the chlorpropamide half-life (t 1/2). The t 1/2 of chlorpropamide was shortened from 49.7 +/- 7.4 to 12.8 +/- 1.1 hr by sodium bicarbonate and prolonged to 68.5 +/- 10.5 hr by ammonium chloride. The 72-hr urinary excretion of chlorpropamide was increased fourfold by alkalinization and decreased to 1/20 of baseline by acidification of the urine. The renal clearance of chlorpropamide correlated with urinary pH, ranging from 1 to 1000 ml/hr at the pH from 5 to 8. Urinary pH is likely to explain at least a part of great interindividual differences in the serum chlorpropamide concentrations during steady-state and variations in amount of urinary metabolites. In chlorpropamide intoxications activated charcoal can reduce absorption and alkalinization of the urine accelerates its elimination.
Collapse
|
17
|
Batenhorst RL, Bustrack JA, Bivins BA, Foster TS. Comparative bioavailability of chlorpropamide tablet and suspension formulations. Clin Pharm 1982; 1:58-61. [PMID: 7184670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The bioavailability of a chlorpropamide tablet formulation chlorpropamide tablet formulation was assessed by comparing it to a reference suspension of chlorpropamide. Eighteen healthy adult men received chlorpropamide 250 mg as a tablet (Diabinese, Pfizer) and suspension in an open two-way crossover study of Latin-square design with a 14-day washout period between treatments. Serial blood samples were obtained by venipuncture for 96 hours for chlorpropamide serum concentration determinations. Serum glucose concentrations were determined at 0, 0.5, 1, 2, and 4 hours. The area under the serum chlorpropamide concentration-time curve (AUC), peak serum chlorpropamide concentration (Cmax), time to Cmax, and mean glucose concentration at each time point for each treatment were compared using a two-tailed Student's t test for paired data (p less than 0.05). Microrate constants for a two-compartment model for oral absorption computed using nonlinear regression were also compared. There were no significant differences between the two formulations regarding AUC, Cmax, time to Cmax, and hypoglycemic response. The absorption rate for the tablet was significantly greater than for the suspension. The results suggest that the oral chlorpropamide tablet and reference suspension are bioequivalent. Although the tablet had a faster absorption rate than the suspension, this probably is not clinically important since both formulations similarly decreased serum glucose concentration.
Collapse
|
18
|
|
19
|
Huupponen R, Lammintausta R. Chlorpropamide bioavailability and pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 1981; 19:331-3. [PMID: 7263111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The pharmacokinetics of chlorproamide was studied in eight healthy volunteers after intravenous and oral dosage. A long elimination half-life with considerable variations between subjects was recorded. The normalized areas under the curve were in close agreement between the subjects, suggesting that they had all absorbed the same magnitude of chlorpropamide. The AUCs after i.v. and p.o. administration did not differ significantly from each other. Thus, the differences in the bioavailability do not seem to be a critical factor in the previously reported large interindividual variations in chlorpropamide steady-state concentrations.
Collapse
|
20
|
|
21
|
Barnett AH, Mace PJ, Pyke DA. Chlorpropamide-alcohol flushing and microangiopathy in insulin-dependent diabetes. Br Med J (Clin Res Ed) 1981; 282:523. [PMID: 6780110 PMCID: PMC1504347 DOI: 10.1136/bmj.282.6263.523] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
22
|
Barnett AH, Leslie RD, Pyke DA. Chlorpropamide-alcohol flushing and proteinuria in non-insulin-dependent diabetics. Br Med J (Clin Res Ed) 1981; 282:522-3. [PMID: 6780109 PMCID: PMC1504306 DOI: 10.1136/bmj.282.6263.522] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
23
|
Abstract
In this report we review the pharmacology of the hypoglycemic sulfonylurea drugs. The early work with sulfonylureas is briefly described. The pharmacokinetics of first-generation sulfonylureas, such as tolbutamide, chlorpropamide, acetohexamide and tolazamide, are described. The first-generation sulfonylureas are compared with second-generation sulfonylureas such as glyburide, glipizide and glibornuride. These latter drugs have a more nonpolar or lipophilic side chain, which results in a marked increase in their hypoglycemic potency. Because of the low serum concentration required for effective therapy, it is necessary to measure the serum concentration of second-generation sulfonylureas by gas-liquid chromatography or radioimmunoassay. The second-generation sulfonylureas do not produce facial flushing after ethanol ingestion (Antabuse effect) and are not uricosuric. Glyburide (but not glipizide or glibornuride) has been evaluated for its effect on water excretion. Glyburide not only does not increase water retention but in fact also increases free water clearance. The second-generation sulfonylureas bind to human serum albumin by nonionic forces in contrast with tolbutamide and chlorpropamide which bind by ionic forces. Thus, anionic drugs such as phenylbutazone, warfarin and salicylate do not displace glyburide from albumin as they displace tolbutamide and chlorpropamide. Therefore, it may be safer to administer the second-generation sulfonylureas than the more polar sulfonylureas when concurrent administration of other pharmacologic agents is likely. The sulfonylurea drugs lower plasma glucose concentrations in diabetic patients by stimulating insulin secretion and by potentiating the biologic effect of the insulin on such tissues as skeletal muscle, fat and liver. The mechanism of the latter so-called extra-pancreatic effect may be activated by increasing the deficient numbers of insulin receptors on muscle, fat or liver cells.
Collapse
|
24
|
Vila JL, Dominguez-Gil AA. [Relationship between pharmacokinetic and pharmacodynamic parameters of chlorpropamide administered to rabbits. II]. Boll Chim Farm 1980; 119:355-60. [PMID: 7459053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
25
|
Sartor G, Melander A, Scherstén B, Wåhlin-Boll E. Influence of food and age on the single-dose kinetics and effects of tolbutamide and chlorpropamide. Eur J Clin Pharmacol 1980; 17:285-93. [PMID: 6995130 DOI: 10.1007/bf00625802] [Citation(s) in RCA: 40] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
26
|
Ueda H, Higashiyama K, Nagai T. Nuclear magnetic resonance study of the binding of tolbutamide and chlorpropamide to bovine serum albumin. Chem Pharm Bull (Tokyo) 1980; 28:1016-21. [PMID: 7418103 DOI: 10.1248/cpb.28.1016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
27
|
|
28
|
Abstract
1. The serum profiles of chlorpropamide obtained following single doses of two tablet preparations and from a suspension formulation have been compared in healthy volunteers. The amounts of chlorpropamide absorbed from the three formulations were similar but the drug was absorbed more rapidly from the suspension than from either tablet formulation. There was a small but therapeutically insignificant difference in the rate of absorption of the drug from the two tablets. 2. Changes in blood glucose concentrations were found to be related to the drug serum profile characteristics of the formulations.
Collapse
|
29
|
Nishihata T, Yata N, Kamada A. Pharmacokinetic behavior of chlorpropamide and sulfadimethoxine in alloxan diabetic rabbits. Chem Pharm Bull (Tokyo) 1978; 26:3353-63. [PMID: 729121 DOI: 10.1248/cpb.26.3353] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
30
|
Nishihata T, Yata N, Kamada A. On the mechanism of increased renal tubular reabsorption of drugs in alloxan diabetic rabbits. Chem Pharm Bull (Tokyo) 1978; 26:3378-83. [PMID: 729122 DOI: 10.1248/cpb.26.3378] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
31
|
Abstract
It is possible to predict plasma concentrations of drugs by measurement in saliva, obviating the need for venipuncture. Using a selection of weakly acidic and basic drugs, we have found this prediction reliable for drugs largely nonionized at normal plasma pH (phenytoin, phenobarbital, antipyrine) but unreliable for ionized drugs (chlorpropramide, tolbutamide, propranolol, meperidine). Deliberate alteration of saliva flow rate and pH using different stimuli have produced twofold changes in saliva drug concentrations. Wide interindividual variability of saliva pH is the likely explanation for the inconstancy of saliva to plasma concentration ratios for ionized drugs.
Collapse
|
32
|
Abstract
A new method of treating dynamic dialysis data to obtain binding parameters for drug-macromolecule interactions is presented. This method allows the determination of binding parameters directly from dialysis data according to a theoretical model. It is not necessary to determine the dialysis rate constant accurately in a separate experiment, and bias is not introduced due to differentiation. The proposed method should be applicable where the drug is substantially bound to the dialysis membrane.
Collapse
|
33
|
|
34
|
Blumenthal SA, Moses AM. Clinical use of the sulfonylurea drugs. Compr Ther 1976; 2:53-8. [PMID: 954381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
35
|
Taylor JA. Pharmacokinetics and biotransformation of chlorpropamide in the rat and dog. Drug Metab Dispos 1974; 2:221-7. [PMID: 4152995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
36
|
|
37
|
|
38
|
|
39
|
Petitpierre B, Perrin L, Rudhardt M, Herrera A, Fabre J. Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. Int J Clin Pharmacol 1972; 6:120-4. [PMID: 4638970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
40
|
Pettipierre B, Fabre J. [The effect of renal insufficiency on the hypoglycemic action of sulfonylureas. Kinetics of chlorpropamide in a case of nephropathy]. Schweiz Med Wochenschr 1972; 102:570-8. [PMID: 5019376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
41
|
Fabre J, Rudhardt M, Petitpierre B, Perrin L. [Kinetics of chlorpropamide in renal insufficiency. Effect of associated therapeutics]. J Urol Nephrol (Paris) 1971; 77:960-2. [PMID: 5151207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
42
|
Nistrup Madsen S, Fog-Moller F, Persson I. Distribution of tolbutamide and chlorpropamide after administration to non-diabetic rats. Eur J Pharmacol 1971; 13:374-80. [PMID: 5577500 DOI: 10.1016/0014-2999(71)90229-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
43
|
|
44
|
|
45
|
|
46
|
|